ddI (Didanosine, Videx): Research
- ddI Resistance in South African Children Failing an Abacavir- or d4T-Based First-Line Regimen (March/April 2013)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- Emtriva + Reyataz + Videx Not as Effective as Combivir + Sustiva in First-Line Therapy, Study Finds (May 28, 2008)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Abacavir, Didanosine Associated With Higher Heart Attack Risk, D:A:D Study Finds (February 5, 2008)
An interview with Jens Lundgren, M.D.
In 15th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Position Statement by the D:A:D Steering Committee (February 4, 2008)
A discussion of the significance of a study examining the association between use of abacavir, didanosine and lamivudine and the risk of myocardial infarction.
To read PDF, click here.
From D:A:D Steering Committee
On TheBodyPRO.com
- Increased Risk of Myocardial Infarction Associated With Abacavir and ddI (February 4, 2008)
From HIV i-Base
On TheBodyPRO.com
- HIV JournalView: Tenofovir + Didanosine: The Downfall of a Lovely Combination (January 2006)
Part of David Wohl, M.D.'s review of the top 10 HIV research reports of 2005.
In HIV JournalView, from TheBodyPRO.com
- ddI + Ribavirin May Cause Mitochondrial Toxicity (September 1, 2005)
In Journal of Acquired Immune Deficiency Syndromes
- HIV JournalView: Study Ties Insulin Resistance to NRTIs, Not PIs (September 2005)
d4T and 3TC are associated with insulin resistance and high insulin levels; indinavir is associated only with elevated insulin levels; and no link to insulin abnormalities is found for AZT or ddI.
From TheBodyPRO.com
- ddI + Tenofovir Combination Linked to Higher Pancreatitis Risk (October 2004)
Quick recap of a report in The Lancet.
In HIV Treatment ALERTS!, from The Center for AIDS
- Micronutrient Supplement Can Improve d4T-, ddI-Related Neuropathy, Study Says (March/April 2004)
In Positively Aware, from Test Positive Aware Network
- High Rate of Virologic Failure With Once-Daily ddI/3TC/TDF (November 2003)
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- Gilead Warns Against Use of Triple-NRTI Regimen 3TC, ddI, Tenofovir (October 14, 2003)
To read PDF, click here.
From U.S. Food and Drug Administration
- Effective Once-Daily HIV Regimen (October 2003)
From the 2nd International AIDS Society Conference.
In HIV Treatment ALERTS!, from The Center for AIDS
- Further Case Report of Lactic Acidosis Linked to Tenofovir/ddI (September 29, 2003)
From aidsmap.com
- A Comparison of AZT/3TC vs. d4T/ddI, Plus Efavirenz, Nevirapine or Indinavir/Ritonavir (September 15, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from TheBodyPRO.com
- Adding ddI Achieves Fall in Viral Load in HAART Patients With Resistance (September 14, 2003)
From aidsmap.com
- HIV-Positive Man Dies of Kidney Failure and Lactic Acidosis Due to Tenofovir/ddI Interaction (April 8, 2003)
From aidsmap.com
- Didanosine and Tenofovir DF Drug-Drug Interaction: Assessment of Didanosine Dose Reduction (February 12, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- New Questions About an Old Combination -- ddI + d4T (January 2003)
To read PDF, click here.
In Project Inform Perspective, from Project Inform
On TheBodyPRO.com
- Tenofovir DF and Didanosine EC: Investigation of Pharmacokinetic Drug-Drug and Drug-Food Interactions (November 21, 2002)
In The 6th International Congress on Drug Therapy in HIV Infection, from TheBodyPRO.com
- Viread-Videx EC Drug Interactions -- What's a Person to Do? (Fall 2002)
To read PDF, click here.
In STEP Perspective, from Seattle Treatment Education Project
On TheBodyPRO.com
|
Advertisement
|
Email
Glossary
